Phaxiam reports very high spectrum of activity its anti-S. aureus phages

Phaxiam Therapeutics announced a very high spectrum of activity of its anti-S. aureus phages against clinical bacterial strains. A retrospective analysis was carried out with 105 clinical Staphylococcus aureus strains which were tested using Phaxiam’s phagogram in the context of clinical trials, salvage therapy and early access program (AAC). The results demonstrated that 98% of these pathogenic S. aureus strains were susceptible to at least one of the two Phaxiam’s anti-S. aureus phages. Phagogram is an in vitro diagnostic, or IVD, test designed to determine the in-vitro activity of Phaxiam’s phages to patients’ bacterial strains. Phagogram is the first CE-marked IVD test dedicated to phage activity evaluation.